Compare Illumina, Inc. (ILMN) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Synopsys, Inc. — how do they compare? Illumina, Inc. trades at $189.78 (market cap $27.94B), while Synopsys, Inc. trades at $386.64 (market cap $72.47B). The key difference: Synopsys, Inc. is far larger — about 2.6× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | SNPS | |
|---|---|---|
Market Cap | $27.94B | $72.47B |
Sector | Health | Technology |
52-Week High | $194.33 | $645.59 |
52-Week Low | $91.00 | $378.46 |
Enterprise Value | $29.33B | $80.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Synopsys (SNPS) trades at $378.47, down 1.51% amid a semiconductor sector downturn. The stock shows bearish technical signals but maintains strong fundamentals with consistent earnings beats and a high analyst buy consensus of 82.76%. Recent news highlights the company's strategic pivot to AI design tools and margin expansion following the Ansys integration.
Outlook remains positive long-term due to SNPS's critical role in AI chip design, though near-term risks include sector volatility and execution of high-margin transitions. The consensus price target of $559.50 implies significant upside, but investors should monitor competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
